drugset / Trial / NCT05133830

Linerixibat and Obeticholic Acid Drug Interaction Study in Healthy Adult Participants

NCT05133830

Phase 1 Completed 52 enrolled GlaxoSmithKline
RandomizedParallel-groupOpen-labelTreatment

Summary

This study aims to investigate the effect of linerixibat on plasma concentrations of obeticholic acid (OCA) and its conjugates in healthy adult participants to inform the potential for drug interaction with coadministration of linerixibat and OCA.

Timeline

Start
2021-11-23
Primary completion
2022-05-31
Completion
2022-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Linerixibat Small molecule
Subject Obeticholic Acid Small molecule

Indications

No indication recorded.